

## **Halma plc ('Halma' or the 'Group')**

### **Acquisition**

Halma, the global group of life-saving technology companies focused on growing a safer, cleaner, healthier future for everyone, every day, today announces that it has acquired Lamidey Noury Medical.

Founded in 1947 and headquartered close to Paris, Lamidey Noury manufactures advanced electrosurgical and associated energy devices which are used in minimally invasive urology, gynaecology, and general surgery. Its products are sold to healthcare providers in over 60 countries.

The cash consideration for Lamidey Noury is €50m (approximately £42m), on a cash- and debt-free basis, to be funded from Halma's existing facilities.

Lamidey Noury's unaudited revenue for the 12 months to October 2024 was €13.6m (approximately £11.4m), with an EBIT margin above the upper end of Halma's target range of 19-23%. Lamidey Noury will be a standalone company within Halma's Healthcare Sector, led by its current management team.

Marc Ronchetti, Group Chief Executive of Halma, commented:

"Lamidey Noury is an exciting acquisition which will bring new minimally invasive surgical product capabilities to our Healthcare Sector. Its advanced products improve patient outcomes and the efficiency of healthcare providers in treating the increasing incidence of urological and gynaecological disease. It is adjacent to our existing presence in diagnosis and biopsy devices for these diseases through Rovers Medical Devices and IZI Medical. We are delighted to welcome Lamidey Noury to Halma and look forward to supporting its development as it continues to scale its business globally."

Guillaume Noury, President of Lamidey Noury said:

"Joining Halma is an exciting opportunity for us. Leveraging Halma's expertise, resources, and global reach will accelerate our growth and innovation. We are confident in our ability to continue delivering high-quality surgical tools to our customers worldwide, while providing new opportunities for our employees and stakeholders. Together, we will continue improving patient outcomes and driving excellence in healthcare."

For further information, please contact:

#### **Halma plc**

Marc Ronchetti, Group Chief Executive	+44 (0)1494 721111
Steve Gunning, Group Chief Financial Officer	
Charles King, Head of Investor Relations	+44 (0) 7776 685948
Clayton Hirst, Director of Corporate Affairs	+44 (0) 7384 796 013

#### **MHP**

Oliver Hughes / Rachel Farrington / Ollie Hoare +44 (0)20 3128 8100 / +44 (0)7817 458 804 / [halma@mhpgroup.com](mailto:halma@mhpgroup.com)

A copy of this announcement, together with other information about Halma, is available at [www.halma.com](http://www.halma.com).

#### **About Halma**

Halma is a global group of life-saving technology companies, focused on growing a safer, cleaner, healthier future for everyone, every day. Its purpose defines the three broad markets it operates in:

- Health - Meeting the increasing demand for better healthcare as chronic illness rises, driven by growing and ageing populations and lifestyle changes.
- Environment - Addressing the impacts of climate change, pollution and waste, protecting life-critical resources and supporting scientific research.
- Safety - Protecting the safety of people and assets as populations grow and the demand on infrastructure increases.

It employs over 8,000 people in more than 20 countries, with major operations in the UK, Mainland Europe, the USA and Asia Pacific. Halma is listed on the London Stock Exchange (LON: HLMA) and is a constituent of the FTSE 100 index.

Halma has been named as one of Britain's Most Admired Companies for the past six years.

For more information [www.halma.com](http://www.halma.com)

**ENDS**

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ACQBABRTMTABBBI